Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
generic:
None (23) ·
(multiple, generic dominant) (1) ·
Anafranil (1) ·
Aurorix (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Dolophine (1) ·
Duragesic (1) ·
DXM (1) ·
DXO (1) ·
Edronax (1) ·
Fetzima (1) ·
Ludiomil (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Nubain (1) ·
Nucynta (1) ·
Opana (1) ·
Parnate (1) ·
Savella (1) ·
Serzone (1) ·
Spravato (1) ·
Stablon (1) ·
Stadol (1) ·
Suboxone (1) ·
Surmontil (1) ·
Talwin (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vicodin (1) ·
Vivactil (1) ·
Zoloft (1)
mechanism:
Mu-opioid receptor agonist (4) ·
Irreversible non-selective MAO inhibitor (3) ·
NMDA antagonist (3) ·
Potent mu-opioid receptor agonist (3) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
NMDA antagonist; sigma receptor agonist (2) ·
Serotonin–norepinephrine reuptake inhibitor (2)
None (54) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
None (54) ·
25 mg (1) ·
Adult: 15–60 mg every 4 hours as needed. (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
Showing below up to 57 results in range #1 to #57.


